A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Migraine

Sponsor: Arteaus Therapeutics, LLC

Location(s): United States


Based on the strength of the Phase 1 results, Arteaus initiated a Phase 2 clinical trial of LY2951742 in patients with frequent migraine.

Study Design

Study ART-01 is a Phase 2, multi-site, double-blind, randomized, placebo-controlled, trial of LY2951742 in patients with frequent migraine to evaluate clinical efficacy, safety, and tolerability. Patients will initially be screened, then begin a baseline assessment period to determine the type, frequency and severity of their headaches. Subsequently, patients will enter the 12-week treatment phase and then a 12-week follow-up period.  It is anticipated that approximately 190 patients will be enrolled in the study. Patients will receive either placebo or LY2951742 administered as a subcutaneous (SC) injection once every other week.

For more information about the study  click here .